Announcements Trials
Browse Landscape

Phase

Phase 2 1

Status

Active not recruiting 1

Sponsor Class

INDUSTRY 1

Study Type

Interventional 1

Sponsor

Cancer Type

Thoracic 1Sarcoma 1Other hematologic neoplasm 1Lymphoid 1Genitourinary 1Gastrointestinal 1CNS 1Breast 1

Conditions

Urinary Bladder Neoplasms 23Prostatic Neoplasms 18Wilms Tumor 12Kidney Neoplasms 11Neoplasm Metastasis 8Carcinoma, Renal Cell 8Urethral Neoplasms 6Sarcoma 6Colorectal Neoplasms 4Breast Neoplasms 4Precursor Cell Lymphoblastic Leukemia-Lymphoma 3Ovarian Neoplasms 3Neoplasms 3Lymphoma, Non-Hodgkin 3Lung Neoplasms 3Ureteral Neoplasms 2Sarcoma, Synovial 2Sarcoma, Endometrial Stromal 2Pheochromocytoma 2Pancreatic Neoplasms 2Neurofibrosarcoma 2Neuroblastoma 2Myeloproliferative Disorders 2Myelodysplastic-Myeloproliferative Diseases 2Multiple Myeloma 2Melanoma 2Malignant mesenchymal tumor 2Liposarcoma 2Leukemia, Myelomonocytic, Chronic 2Leukemia, Myeloid, Chronic-Phase 2

Interventions

olaparib 2Carboplatin 2pembrolizumab 1liposomal doxorubicin 1Taxes 1Paclitaxel 1Lomustine 1Irinotecan 1Gemcitabine 1Doxorubicin 1CYH33 1Albumin-Bound Paclitaxel 13-(5-fluorobenzofuran-3-yl)-4-(5-methyl-5H-(1,3)dioxolo(4,5-f)indol-7-yl)-pyrrole-2,5-dione 1

Date Range

30 days90 days1 yearAll

Options

Has results Has announcements

Clinical Trials

1 trials
RecentStart dateEnrollment
Hereditary Sensory and Autonomic Neuropathies × Doxorubicin × Genitourinary × Clear all
NCT03678883 2026-04-03

9-ING-41 in Patients With Advanced Cancers

Actuate Therapeutics Inc.

Phase 2 Active not recruiting
350 enrolled
BreastCNSGastrointestinalGenitourinaryLymphoidOther hematologic neoplasmSarcomaThoracic

Bone Neoplasms, Breast Neoplasms, Glioma, Kidney Neoplasms, Lung Neoplasms, Lymphoma, Non-Hodgkin, Neoplasm Metastasis, Neoplasms, Hereditary Sensory and Autonomic Neuropathies, Pancreatic Neoplasms, Sarcoma, Colorectal Neoplasms, Leukemia-Lymphoma, Adult T-Cell

Data powered by HemOnc (CC BY 4.0) Colophon âš¡